AG真人官方

Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), reported a sale of 10,000 ordinary shares on 08/22/2025 at a price of $10 per share, executed under a Rule 10b5-1 trading plan adopted March 13, 2025. After the reported disposition, Mr. Verdine beneficially owned 285,217 ordinary shares. The Form 4 was signed by Mr. Verdine on 08/26/2025 and indicates the transaction was effected pursuant to the specified 10b5-1 plan.

Paul B. Bolno, President and CEO and Director of Wave Life Sciences Ltd. (WVE), reported an insider sale. On 08/22/2025 he sold 217,351 ordinary shares under a Rule 10b5-1 trading plan adopted May 19, 2025. The weighted-average sale price was $10.098, with individual sale prices ranging from $10.00 to $10.27. After the reported transactions, the filing shows 121,000 ordinary shares beneficially owned by the reporting person. The Form 4 was signed on 08/26/2025 and notes the seller can provide detailed execution pricing by request.

Wave Life Sciences (WVE) submitted a Form 144 notice proposing the sale of 217,351 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $2,121,345.76, with an approximate sale date of 08/22/2025. The filing shows the shares were acquired as 26,495 Restricted Stock Units on 02/15/2021 and 190,856 Founders Shares on 03/31/2015. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard signer representation that they are not aware of any undisclosed material adverse information.

Wave Life Sciences Ltd. (WVE) Form 144 notice: An intended sale of 25,000 common shares is being reported with Morgan Stanley Smith Barney listed as the broker and an approximate aggregate market value of $244,000. The filing shows 159,140,460 shares outstanding and an approximate sale date of 08/22/2025. The shares were acquired on 03/05/2025 through previously exercised stock options and payment was made in cash on the same date. The filer also disclosed a prior sale within the past three months: 30,000 common shares sold on 06/13/2025 under a 10b5-1 plan for gross proceeds of $208,602. The notice includes the standard signature attestations that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 where applicable.

Wave Life Sciences director Aik Na Tan executed a Rule 10b5-1 plan transaction on 08/15/2025 that exercised and sold share options. The reporting person exercised 21,000 vested options at an exercise price of $9.13 per share, receiving 21,000 ordinary shares, and simultaneously sold 21,000 shares at $9.25 per share. Following these transactions the reporting person beneficially owned 40,388 ordinary shares, down from 61,388 before the sale. The 10b5-1 plan was adopted on March 13, 2025. The Form 4 is signed by Aik Na Tan on 08/19/2025.

Wave Life Sciences (WVE) Form 144 notices a proposed sale of 21,000 common shares by a person who exercised stock options on 08/15/2025 and intends to sell through Morgan Stanley Smith Barney LLC on NASDAQ at an aggregate market value of $194,250.00. The filing reports 159,140,460 shares outstanding. The same account sold 1,127 shares on 08/05/2025 for gross proceeds of $9,861.25. The seller represents they are not aware of undisclosed material adverse information about the issuer.

Form 4 filed for Wave Life Sciences (WVE) reports director compensation awards and large Fund holdings. On 08/11/2025 RA Capital entities and affiliated individuals disclosed awards and holdings related to Dr. Peter Kolchinsky, a director. The filing shows a grant of 12,700 restricted share units (RSUs) and an award of 76,200 share options with an $8.105 exercise price. The RSUs and options vest on the earlier of the issuer's 2026 annual general meeting or August 11, 2026, and the options expire August 11, 2030.

The filing further reports 28,815 shares beneficially owned following the reported transaction(s) (indirect) and that RA Capital Healthcare Fund, L.P. directly holds 18,202,009 shares. Footnotes state the RSUs/options are held for the benefit of the Fund and that the reporting parties disclaim beneficial ownership except for pecuniary interest.

Mark Corrigan, a director of Wave Life Sciences Ltd. (WVE), received equity awards on 08/11/2025 under the company鈥檚 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 12,700 restricted share units (RSUs) and a grant of a share option for 76,200 ordinary shares with an exercise price of $8.105. These awards were reported on a Form 4 disclosing insider activity.

The RSUs vest 100% on the earlier of the company鈥檚 2026 annual general meeting or August 11, 2026. The option also vests 100% by that same earlier date and has an expiration date of 08/11/2030. After the reported transactions, the filing shows the reporting person beneficially owns 44,930 ordinary shares and holds 76,200 options referenced in the filing.

Wave Life Sciences Ltd. (WVE) Director Aik Na Tan reported equity awards on 08/11/2025 under the company鈥檚 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 25,400 restricted share units (RSUs) that vest 50% on the earlier of the 2026 annual general meeting or August 11, 2026 and 50% on the earlier of the 2027 annual general meeting or August 11, 2027. The reporting person was also granted a share option for 152,400 ordinary shares with an exercise price of $8.105, vesting 12.5% quarterly beginning August 11, 2025 over two years and expiring on 08/11/2030. After these reported transactions the form lists 40,388 ordinary shares and 152,400 derivative securities beneficially owned by the reporting person.